Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530366 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20075455 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL21210132 | 0.90 | MEN1 (0.64) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL18085407 | 0.90 | MEN1 (0.64) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4598805 | 0.88 | MEN1 (0.53) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL29974865 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20001957 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20073977 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL15723437 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL16234280 | 0.83 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | MEN1 4346/4885GAA 1688/4885KMT2A 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.